Secukinumab Rapidly Reduces Hidden Joint Inflammation in Psoriasis Patients
Secukinumab, an IL-17A inhibitor, significantly reduces subclinical enthesitis in patients with moderate-to-severe plaque psoriasis, according to a study published in the journal Skin. By targeting inflammation at the attachment points of tendons and ligaments before joint pain begins, this treatment may prevent irreversible structural damage associated with psoriatic arthritis (PsA), researchers from The Second Affiliated … Read more